Adaptive Study Design OK For Single-Arm Trials, FDA Says
Executive Summary
A newly finalized guidance document offers the US agency’s take on how and when clinical trials can be modified midstream. It includes some revisions from a draft version, including more attention paid the possibility of adaptive single-arm trials.
You may also be interested in...
Single-Arm Studies Can Have Adaptive Designs, Industry Tells FDA
FDA's recent draft guidance on adaptive device trial designs is a good step, but it should be more inclusive of single-arm studies and not just randomized trials, AdvaMed says.
Modifying Clinical Studies Midstream Can Be Done, With Caution, FDA Says
Adaptive device clinical trials, where study is designed in anticipation of midstream changes, are the focus on a new FDA draft guidance. Adaptive trials can reduce the duration and cost of a study without undermining its integrity, but the practice should be applied with caution, FDA says.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.